aTYR PHARMA INC ATYR
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2015 · data as of November 13, 2026
aTYR PHARMA INC (ATYR) is a healthcare company listed in the US with a market value of about $16M. In fiscal year 2025 it had revenue of $190000 and net income of -$74M, a net margin of -39009.5%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.3, 5-year revenue growth of -55% a year, a 5-year average ROIC of -64%.
About aTYR PHARMA INC
aTYR PHARMA INC is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2015. Revenue went from $422000 in 2019 to $190000 in 2025, a decline of about 12.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 227% over three years (dilution for shareholders). It spends 31694% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190000 | $235000 | $353000 | $10M | $0 | $10M | $422000 | — | — | — |
| Net income | -$74M | -$64M | -$50M | -$45M | -$34M | -$16M | -$16M | -$35M | -$48M | -$58M |
| Free cash flow | -$62M | -$69M | -$37M | -$44M | -$33M | -$16M | -$20M | -$32M | -$44M | -$53M |
| EPS (diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | $-7.03 | $-16.11 | $-26.13 | $-34.13 |
| Net margin | -39009.5% | -27243.8% | -14274.5% | -436.5% | — | -155.2% | -3844.6% | — | — | — |
| ROIC | -98.7% | -83.0% | -52.7% | -54.9% | -30.7% | -46.9% | -69.8% | -61.7% | -44.4% | -80.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $45.17, 640% above the current price; targets range from $5.00 to $160.00; the consensus rating is “Hold”; expected EPS is $-23.97 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is aTYR PHARMA INC’s P/E ratio?
About 0.3, based on the last twelve months of diluted earnings per share.
Does aTYR PHARMA INC pay a dividend?
Not currently.
Is aTYR PHARMA INC a good stock to buy?
We do not give buy or sell advice. aTYR PHARMA INC scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.